MRI activity appeared to be a more sensitive measure of disease activity in secondary progressive multiple sclerosis (SPMS) than relapses, an analysis of two datasets showed. "When we interrogated a ...

Please provide your email address to receive an email when new articles are posted on . SAN DIEGO — Advances in the ability to measure chronic, active inflammation in MS using MRI and positron ...

Even with disease-modifying therapies, patients who have chronically active inflammatory MS lesions can expect an aggressive disease course and poor outcomes. A new study shows that patients with ≥4 ...

In relapse-remitting multiple sclerosis (MS), people experience periods of high MS activity where they have more symptoms or imaging tests show inflammation. Between these periods, the condition might ...

NASHVILLE, Tennessee — A second-generation anti-CD40L monoclonal antibody suppresses multiple sclerosis (MS) disease activity on MRI to an uncommonly high degree, new trial data suggested. Researchers ...

The investigational drug tolebrutinib effectively reduces brain lesions in patients with highly active relapsing-remitting multiple sclerosis (RRMS), new research suggests. After 12 weeks of treatment ...

An article published today in the journal Lancet Neurology evaluates the risk of recurrence of active disease in older patients with multiple sclerosis after discontinuing disease-modifying therapies.

If you have secondary progressive multiple sclerosis (SPMS), your doctor may have described it as active or inactive. You may be wondering what these terms mean and why they matter. If were at a point ...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to ...